Model N Acquires Kalderos to Strengthen Pharmaceutical Revenue Management

Key Facts

1Model N announced the acquisition of Kalderos to expand its 340B capabilities and gross-to-net revenue management.

In a move reflecting the accelerating consolidation within the healthcare IT sector, Model N has announced the acquisition of Kalderos to bolster its revenue management capabilities. According to reports, the deal is designed to expand the company's 340B program solutions and gross-to-net revenue management. Model N aims to leverage this acquisition to help pharmaceutical manufacturers identify duplicate discounts earlier and navigate complex regulatory environments more efficiently.

This acquisition comes as the pharmaceutical industry faces mounting challenges in claims management, where industry estimates suggest revenue leakage significantly pressures profit margins. Compared to peers in vertical software, Model N is strengthening its position as an integrated platform linking regulatory compliance with profit optimization. Per market data, demand for drug pricing transparency tools has grown notably over the past year amid increased legislative scrutiny in the United States.

From a trading perspective, investors are monitoring how this acquisition will impact the company's financial performance in upcoming quarters. Looking at the economic calendar, the market awaits the U.S. Producer Price Index (PPI) release on June 11, 2026, which may influence broader tech sector sentiment. Focus remains on Model N’s ability to integrate Kalderos’ technology to mitigate discount claim errors and ensure sustainable revenue growth.